134 related articles for article (PubMed ID: 36371408)
1. Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19.
Gobeil P; Pillet S; Boulay I; Charland N; Lorin A; Cheng MP; Vinh DC; Boutet P; Van Der Most R; Roman F; Ceregido MA; Landry N; D'Aoust MA; Ward BJ
Nat Commun; 2022 Nov; 13(1):6905. PubMed ID: 36371408
[TBL] [Abstract][Full Text] [Related]
2. Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines.
Dubé C; Paris-Robidas S; Andreani G; Gutzeit C; D'Aoust MA; Ward BJ; Trépanier S
Vaccine; 2022 Jun; 40(30):4017-4025. PubMed ID: 35654621
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities.
Charland N; Gobeil P; Pillet S; Boulay I; Séguin A; Makarkov A; Heizer G; Bhutada K; Mahmood A; Trépanier S; Hager K; Jiang-Wright J; Atkins J; Saxena P; Cheng MP; Vinh DC; Boutet P; Roman F; Van Der Most R; Ceregido MA; Dionne M; Tellier G; Gauthier JS; Essink B; Libman M; Haffizulla J; Fréchette A; D'Aoust MA; Landry N; Ward BJ
NPJ Vaccines; 2022 Nov; 7(1):142. PubMed ID: 36351931
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19.
Ward BJ; Gobeil P; Séguin A; Atkins J; Boulay I; Charbonneau PY; Couture M; D'Aoust MA; Dhaliwall J; Finkle C; Hager K; Mahmood A; Makarkov A; Cheng MP; Pillet S; Schimke P; St-Martin S; Trépanier S; Landry N
Nat Med; 2021 Jun; 27(6):1071-1078. PubMed ID: 34007070
[TBL] [Abstract][Full Text] [Related]
5. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
6. Lack of effects on female fertility or pre- and postnatal development of offspring in rats after exposure to AS03-adjuvanted recombinant plant-derived virus-like particle vaccine candidate for COVID-19.
Dubé C; Paris-Robidas S; Primakova I; Destexhe E; Ward BJ; Landry N; Trépanier S
Reprod Toxicol; 2022 Jan; 107():69-80. PubMed ID: 34838689
[TBL] [Abstract][Full Text] [Related]
7. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
8. A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern.
Schultz BM; Melo-González F; Duarte LF; Gálvez NMS; Pacheco GA; Soto JA; Berríos-Rojas RV; González LA; Moreno-Tapia D; Rivera-Pérez D; Ríos M; Vázquez Y; Hoppe-Elsholz G; Andrade-Parra CA; Vallejos OP; Piña-Iturbe A; Iturriaga C; Urzua M; Navarrete MS; Rojas Á; Fasce R; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Grifoni A; Sette A; Zeng G; Meng W; ; González-Aramundiz JV; González PA; Abarca K; Kalergis AM; Bueno SM
mBio; 2022 Aug; 13(4):e0142322. PubMed ID: 35946814
[TBL] [Abstract][Full Text] [Related]
9. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
[TBL] [Abstract][Full Text] [Related]
10. Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern.
Khorattanakulchai N; Manopwisedjaroen S; Rattanapisit K; Panapitakkul C; Kemthong T; Suttisan N; Srisutthisamphan K; Malaivijitnond S; Thitithanyanont A; Jongkaewwattana A; Shanmugaraj B; Phoolcharoen W
J Med Virol; 2022 Sep; 94(9):4265-4276. PubMed ID: 35615895
[TBL] [Abstract][Full Text] [Related]
11. Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines.
Lu L; Chen LL; Zhang RR; Tsang OT; Chan JM; Tam AR; Leung WS; Chik TS; Lau DP; Choi CY; Fong CH; Cai JP; Tsoi HW; Choi CY; Zhang X; Abdullah SMU; Chan BP; Chan KH; Yuen KY; Hung IF; To KK
EBioMedicine; 2022 May; 79():103986. PubMed ID: 35398786
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
[TBL] [Abstract][Full Text] [Related]
13. A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice.
Zhou B; Song S; Guo H; Zhou X; Fan Q; Liu W; Cheng L; Ge X; Ju B; Zhang Z
J Med Virol; 2022 Aug; 94(8):3992-3997. PubMed ID: 35474319
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
15. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
[TBL] [Abstract][Full Text] [Related]
16. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
Arunachalam PS; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Röltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Spencer S; Doyle-Meyers L; Bohm RP; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O'Hagan DT; Van Der Most R; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar MS; King NP; Veesler D; Pulendran B
Nature; 2021 Jun; 594(7862):253-258. PubMed ID: 33873199
[TBL] [Abstract][Full Text] [Related]
17. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination.
Graninger M; Camp JV; Aberle SW; Traugott MT; Hoepler W; Puchhammer-Stöckl E; Weseslindtner L; Zoufaly A; Aberle JH; Stiasny K
Front Immunol; 2022; 13():888794. PubMed ID: 35711424
[TBL] [Abstract][Full Text] [Related]
19. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK
Front Immunol; 2021; 12():793953. PubMed ID: 34899762
[TBL] [Abstract][Full Text] [Related]
20. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]